Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

被引：4
|
作者：
Macaulay, V. M.
Middleton, M. R.
Eckhardt, S. G.
Juergens, R. A.
Rudin, C. M.
Manukyants, A.
Gogov, S.
Poondru, S.
Gedrich, R.
Gadgeel, S. M.
机构：
[1] Univ Oxford, Oxford, England
[2] Oxford Radcliffe Hosp, Oxford, England
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] OSI Pharmaceut, Oxford, England
[7] Astellas Pharma, Boulder, CO USA
[8] OSI Pharmaceut, Boulder, CO USA
[9] Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3098
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
    Macaulay, V. M.
    Middleton, M. R.
    Eckhardt, S. G.
    Juergens, R. A.
    Stephens, A. W.
    Poondru, S.
    McCarthy, S. P.
    Gadgeel, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors.
    Carden, C. P.
    Kim, E. S.
    Jones, R. L.
    Alam, S. M.
    Johnson, F. M.
    Stephens, A. W.
    Poondru, S.
    Gedrich, R.
    Lippman, S. M.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.
    Evana, T.
    Lindsay, C. R.
    Chan, E.
    Tait, B.
    Michael, S. A.
    Day, S.
    Stephens, A. W.
    Franke, A.
    Poondru, S.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.
    Harb, W. A.
    Sessa, C.
    Hirte, H. W.
    Kaye, S. B.
    Simantov, R.
    Banerjee, S. N.
    Christinat, A.
    Sternberg, D. W.
    Singh, M.
    Light, R.
    Poondru, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Pharmacodynamic biomarkers for OSI-906, an insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors
    Gedrich, Richard
    Poondru, Srini
    Stephens, Andrew
    Logan, Tiffany
    Hart, Karen
    Buck, Elizabeth
    Carden, Craig
    Lindsay, Colin
    Kaye, Stanley
    Kim, Edward
    Evans, Jeff
    Puzanov, Igor
    Epstein, David
    Miglarese, Mark
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [6] Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors
    Lindsay, C. R.
    Chan, E.
    Evans, T. R.
    Campbell, S.
    Bell, P.
    Stephens, A. W.
    Franke, A.
    Poondru, S.
    Rothenberg, M. L.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Combination strategies for OSI-906, a small molecule inhibitor of the insulin-like growth factor receptor, IGF-1R
    Buck, E.
    Eyzaguirre, A.
    Rosenfeld-Franklin, M.
    Ji, Q.
    Mulvihill, M.
    Wild, R.
    Epstein, D.
    Iwata, K.
    Haley, J.
    Pachter, J.
    Miglarese, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 43 - 43
  • [8] A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
    Puzanov, Igor
    Lindsay, Colin R.
    Goff, Laura
    Sosman, Jeff
    Gilbert, Jill
    Berlin, Jordan
    Poondru, Srinivasu
    Simantov, Ronit
    Gedrich, Rich
    Stephens, Andrew
    Chan, Emily
    Evans, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2015, 21 (04) : 701 - 711
  • [9] Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.
    Harb, Wael A.
    Sessa, Cristiana
    Hirte, Hal W.
    Kaye, Stanley B.
    Banerjee, Susana N.
    Christinat, Alexandra
    Simantov, Ronit
    Singh, Margaret
    Sternberg, David W.
    Light, Rebecca
    Poondru, Srinivasu
    Naumann, R. Wendel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
    Jones, Robin L.
    Kim, Edward S.
    Nava-Parada, Pilar
    Alam, Salma
    Johnson, Faye M.
    Stephens, Andrew W.
    Simantov, Ronit
    Poondru, Srinivasu
    Gedrich, Rich
    Lippman, Scott M.
    Kaye, Stan B.
    Carden, Craig P.
    CLINICAL CANCER RESEARCH, 2015, 21 (04) : 693 - 700
12345